A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer

被引：0
|
作者：
Vergote, I. [1 ]
Dean, E. [2 ]
Lassen, U. [3 ]
de Bono, J. [4 ]
Drew, Y. [5 ]
Machiels, J-P. [6 ]
Nielsen, D. [7 ]
Arkenau, H-T. [8 ]
Forster, M. [9 ]
Jones, R. [10 ]
Slomovitz, B. [11 ]
Spicer, J. [12 ]
Johnson, M. [13 ]
Cornez, N. [14 ]
Gennigens, C. [15 ]
Fulton, B. [16 ]
Lisby, S. [17 ]
Basse, L. [18 ]
Coleman, R. [19 ]
Hong, D. S. [20 ]
机构：
[1] Univ Hosp Leuven, Gynaecol Verloskunde, Leuven, Belgium
[2] Christie NHS Fdn Trust, Clin Trials Unit, Manchester, Lancs, England
[3] Rigshosp, Dept Oncol, Phase Unit 1, Copenhagen, Denmark
[4] Royal Marsden Hosp, Inst Canc Res, Sect Med, Sutton, Surrey, England
[5] Newcastle Gen Hosp, Freeman Hosp, Northern Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England
[6] Roi Albert II, Oncol, Brussels, Belgium
[7] Herlev & Gentofte Hosp, Dept Oncol, Herlev, Denmark
[8] Sarah Cannon Res Inst SCRI UK, Oncol, London, England
[9] UCL, Canc Inst, Oncol, London, England
[10] Velindre Hosp, Velindre Canc Ctr, Oncol, Cardiff, S Glam, Wales
[11] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
[12] Kings Coll London, Guys Hosp, Oncol, London, England
[13] Sarah Cannon Res Inst, Oncol, Nashville, TN USA
[14] Ctr Hosp Univ & Psychiat Mons Borinage, Oncol, Mons, Belgium
[15] Ctr Hosp Uuniv Sart Tilman, Oncol, Liege, Belgium
[16] Beatson West Scotland Canc Ctr, Oncol, Glasgow, Lanark, Scotland
[17] Genmab AS, Med Dept, Copenhagen, Denmark
[18] Genmab, Med Dept, Copenhagen, Denmark
[19] MD Anderson Canc Ctr, Oncol, Houston, TX USA
[20] Univ Texas MD Anderson Canc Ctr, Phase Unit 1, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
931O
引用
收藏
页数：2
相关论文
共 50 条
  • [31] INNOVATV 301/ENGOT-CX12/GOG-3057: TISOTUMAB VEDOTIN VS INVESTIGATOR'S CHOICE CHEMO IN SECOND- OR THIRD-LINE RECURRENT OR METASTATIC CERVICAL CANCER
    Vergote, I. B.
    Randall, L.
    Kalbacher, E.
    Madsen, K.
    Van Nieuwenhuysen, E.
    Gonzalez-Martin, A.
    Lorusso, D.
    Soumaoro, I.
    Jain, S.
    Slomovitz, B.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A1 - A1
  • [32] A phase II study of sintilimab plus anlotinib for Chinese patients (pts) with persistent, recurrent, or metastatic cervical cancer (CC)
    Xu, Q.
    Chen, C.
    Sun, Y.
    Huang, Z.
    Lin, Y.
    Liu, J.
    Li, L.
    Li, Z.
    Pan, J.
    Chen, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S640 - S640
  • [33] A phase II study of sintilimab plus anlotinib for Chinese patients (pts) with persistent, recurrent or metastatic cervical cancer (CC)
    Xu, Qin
    Chen, Chuanben
    Sun, Yang
    Huang, Zhangzhou
    Lin, Yibin
    Liu, Jing
    Li, Li
    Li, Zirong
    Pan, Junping
    Chen, Ying
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S78 - S78
  • [34] TISOTUMAB VEDOTIN (TV) plus BEVACIZUMAB OR PEMBROLIZUMAB OR CARBOPLATIN IN RECURRENT/METASTATIC CERVICAL CANCER (R/MCC): PHASE 1B/2 ENGOT-CX8/GOG-3024/INNOVATV 205 STUDY DOSE-ESCALATION RESULTS
    Monk, B.
    Van Gorp, T.
    Lorusso, D.
    O'Cearbhaill, R. Eilish
    Westermann, A.
    Banerjee, S.
    Collins, D.
    Klat, J.
    Madsen, K.
    Baurain, J-F
    Jackson, A.
    Boere, I.
    Pignata, S.
    Gort, E.
    Moroney, J.
    Soumaoro, I.
    Andreassen, Cm
    Nicacio, L.
    Gennigens, C.
    Vergote, I.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A7 - A8
  • [35] The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study
    Yu, Jiangtao
    Xu, Ziwen
    Li, Anyang
    Zhang, Jindi
    Wang, Yi
    Zhao, Hongqin
    Zhu, Haiyan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 3419 - 3424
  • [36] Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer
    Richel, O
    Vörding, PJZVS
    Rietbroek, R
    Van der Velden, J
    Van Dijk, JDP
    Schilthuis, MS
    Westermann, AM
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 680 - 685
  • [37] Tisotumab vedotin versus investigator's choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG 3057, trial in progress).
    Vergote, Ignace
    Monk, Bradley J.
    Coleman, Robert L.
    Randall, Leslie M.
    Fujiwara, Keiichi
    Marth, Christian
    Woelber, Linn Lena
    Van Nieuwenhuysen, Els
    Cibula, David
    Calvert, Paula
    Boere, Ingrid
    Gonzalez-Martin, Antonio
    Kalbacher, Elsa
    Colombo, Nicoletta
    Lorusso, Domenica
    Banerjee, Susana N.
    Maluf, Fernando C.
    Soumaoro, Ibrahima
    Slomovitz, Brian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Phase II study on pemetrexed in advanced and/or recurrent cervical cancer patients: a MITO study
    Ferrandina, G.
    Lorusso, D.
    Ludovisi, M.
    Pignata, S.
    Sorio, R.
    Mangili, G.
    Breda, E.
    Legge, F.
    Pisconti, S.
    Scambia, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] A phase I/IIa study of the whole-cell vaccine BriaVax™ in metastatic or locally recurrent breast cancer patients (NCT00095862)
    Wiseman, C. L.
    Lacher, M.
    CANCER RESEARCH, 2017, 77
  • [40] Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer
    Kim, JG
    Sohn, SK
    Kim, DH
    Baek, JH
    Sung, WJ
    Park, JY
    Kim, TB
    Jung, HY
    Yu, WS
    Lee, KB
    ONCOLOGY, 2005, 68 (2-3) : 190 - 195
12345